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http://dx.doi.org/10.1016/j.celrep.2014.05.004Steffann et al. (2014) highlight significant
differences in predicting the transmission
of mitochondrial DNA (mtDNA) mutations
by preimplantation genetic diagnosis
(PGD) in human and rhesus macaque
embryos. We previously demonstrated
considerable segregation of mtDNA vari-
ants betweendaughter blastomereswithin
a monkey 8-cell embryo, implying that
sampling and analyzing of one or two blas-
tomeresmay not be fully predictive of total
mutation load in the remaining embryo.
Moreover, monkey offspring produced
from heteroplasmic embryos were nearly
homoplasmic, suggesting thatmtDNAmu-
tation levels may increase drastically due
to a genetic bottleneck (Lee et al., 2012).
The authors reviewed several studies
describing mtDNA mutation distribution
among blastomeres in preimplantation
human embryos. Analysis of two biopsied
blastomeres from each embryo demon-
strated comparable mtDNA mutation
levels. Thus, the authors argue that PGD
is a highly reliable approach to selecting
embryos with sufficiently low mtDNA
mutation levels for transfer.
As an explanation for differences seen
between nonhuman primate and human
embryos, theauthorspoint out thatour rhe-
sus monkey study is based on an ‘‘artifi-
cial’’ mixture of two mtDNA haplotypes in
unfertilized oocytes, whereas hetero-
plasmy in human embryos occurs ‘‘natu-
rally.’’ As we discussed in our study, we
cannot exclude that such an extreme
case of heteroplasmy involving mitochon-
drial sequence polymorphisms between
two distant genomes could have contrib-
uted to the segregation patterns seen in
monkey.Cell RHowever, differences in the specific
molecular techniques used to measure
mtDNA heteroplasmy levels in human
and monkey studies may also have
affected the interpretation of results. In
particular, our study used ARMS-qPCR,
a highly sensitive quantitative assay that
allows accurate assessment of hetero-
plasmy load at a single-cell level (Lee
et al., 2012). In contrast, the human
studies were based on semiquantitative
fluorescent PCR followed by restriction
enzyme digestion, which is associated
with higher technical errors in hetero-
plasmy assessment due to heteroduplex
formation or incomplete digestion (Mon-
not et al., 2011).
Regardless of the technical validity of
mtDNA mutation assessment, the ulti-
mate validation of PGD success is the
birth of healthy children with very low or
undetectable mtDNA mutation load. The
authors cite live births of four children
who were conceived by IVF with embryo
selection post-PGD in families carrying
mtDNA mutations (Monnot et al., 2011;
Steffann et al., 2006; Treff et al., 2012).
Although very limited clinical follow-up
was reported in these cases, it is on the
basis of these studies that Steffann et al.
conclude that PGD is a reliable technique
for lowering or completely eliminating the
maternal transmission of mtDNA muta-
tions to children.
One of these four reported PGD cases
involved a family affected with mitochon-
drial encephalomyopathy, lactic acidosis,
and stroke-like episodes (MELAS) syn-
drome due to the common m.3243A>G
mutation in mtDNA (Treff et al., 2012).
After two IVF cycles and trophectodermeports 7, 935–937, May 22, 2014 ª2014 The Aubiopsy, a male embryo with the lowest
mutation load (12%) was identified and
transferred, resulting in viable pregnancy.
Although the authors’ report implied that
the baby was healthy at birth and unlikely
to manifest symptoms of MELAS later in
life, the actual clinical details of that case
were significantly more complicated.
Specifically, the infant was delivered
pre-term at 34 3/7 weeks’ gestation,
weighing 1,890 g due to severe pre-
eclampsia with placental atresia. The
child then presented to the Mitochon-
drial-Genetics Clinic at The Children’s
Hospital of Philadelphia with multiple
medical problems that included a
cyanotic spell associated with hypoxemia
at 1 month of age, recurrent hypoglyce-
mia (53–64 mg/dl) that self-resolved over
time, recurrent hospitalizations for infec-
tions with prolonged recovery and associ-
ated dehydration, a prolonged period of
projectile vomiting associated with
C. difficile infection, a prolonged febrile
seizure, gastresophageal reflux disease,
mild developmental delays, and behav-
ioral problems including mild hyperactivi-
ty, difficulty calming, frequent temper
tantrums, head tapping, head banging
on the wall and floor, and spinning.
Upon physical exams at 6 weeks and
18 months of age, he was found to have
decreased pupil photoreactivity and
several minor dysmorphic features,
including relative macroscaphocephaly,
mildly coarse facies, thickened superior
ear helix, epicanthal folds, short sublin-
gual frenulum, mild fifth finger clinodac-
tyly, and small umbilical hernia. His brain
MRI at age 15 months revealed promi-
nence of the ventricular system and935thors Open access under CC BY-NC-ND license.
extra-axial cerebrospinal fluid; prominent
Virchow-Robin spaces; pineal cyst;
increased FLAIR signal involving the pos-
terior periventricular white matter, sug-
gestive of incomplete myelination; and
multiple areas of scattered punctate
signal abnormality, most extensively in
the cerebellum, right temporal-occipital
border, and right occipital lobe, that
were indicative of prior intracranial and
intraventricular hemorrhage.
Metabolic studies of his blood and urine
identified intermittent mild lactic acidemia
and an elevated ratio of lactate to pyru-
vate—including an occurrence at the
time of an intercurrent febrile illness
(Table S1)—generalized aminoaciduria,
and elevated triglycerides (245 mg/dl;
normal, < 125). Multiple genetic studies
did not reveal chromosomal copy-num-
ber aberrations or nuclear gene muta-
tions. However, ARMS-qPCR analysis
performed by a CLIA-certified mitochon-
drial genetics diagnostics laboratory on
samples collected from the boy at the
ages of 6 weeks and 18 months demon-
strated mutant m.3243A>G heteroplasmy
loads of 47% and 46% in blood and 52%
and 42% in urine, respectively (Table S1).
It is not clear whether this child’s com-
plex neurologic, developmental, and
multisystem problems relate to his
m.3243A>G mutation, the biopsy itself,
or other aspects of the IVF procedure.
While some of the child’s features are
neither specific nor typical for MELAS,
they could potentially relate to problems
experienced in the perinatal course,
such as preeclampsia and intrauterine
growth restriction, which are known com-
plications of the m.3243A>G mutation.
Studies on the correlation between
m.3243A>G mutation and clinical mani-
festations suggest that a 50% hetero-
plasmy level is on the borderline of where
phenotypic expression of MELAS is ex-
pected (Jeppesen et al., 2006). Regard-
less, careful clinical follow-up throughout
the patient’s life is indicated.
This case highlights that important un-
certainties remain in predicting ‘‘safe’’
mtDNA mutation levels sufficient to
assure long-term health in children born
after PGD. A phenomenon that might be
relevant to his outcome is the existence
of the mtDNA bottleneck that occurs dur-
ing the early peri-implantation period,
suggesting that mutation levels in liveborn936 Cell Reports 7, 935–937, May 22, 2014 ªchildren may change significantly
compared to heteroplasmy levels deter-
mined in preimplantation embryos. As
recognized above, another potential
problem may relate to limitations of the
technical accuracy of the specific molec-
ular assays implemented for quantifica-
tion of mtDNA mutation levels at a sin-
gle-cell level in biopsied preimplantation
embryos.
Although PGD appeared more suc-
cessful in predicting mtDNA mutation
levels in the other cases of three liveborn
children cited by Steffann et al., additional
limitations of this methodmust be consid-
ered (Wallace and Chalkia, 2013). A major
concern is that PGD simply selects for the
embryo having the lowest heteroplasmy
level and may reduce, but is unlikely to
eliminate, the risk of transmitting mtDNA
mutations. Additionally, women may not
produce oocytes, and hence embryos,
with levels of mutant mtDNA that are low
enough to be acceptable for transfer. No
exact recommendations exist for the
determination of an acceptable hetero-
plasmy level that may be ‘‘safe’’ to select,
because this likely depends on the muta-
tion type, specific diseasemanifestations,
and family history (Poulton and Brede-
noord, 2010). Given the possibility of
random and rapid changes in mtDNA het-
eroplasmy, any level of mutant mtDNA
present in embryos could lead to clinical
disease that presents either in childhood
or later in life and is more likely to result
in maternal transmission of disease in
future generations. A recently reported
model of mtDNA heteroplasmy inheri-
tance predicts that transfer of an embryo
having a mutation level above 5% will
have a significant chance of disease
recurrence (Samuels et al., 2013). There-
fore, many families now request transfers
of embryos with a mutation threshold of
5%or less (Sallevelt et al., 2013), although
these may not be present in a given IVF
cycle.
Another important PGD-related consid-
eration is that at least two cells are
removed from the 8-cell embryo, which
significantly reduces its developmental
potential and chance of developing into
a viable pregnancy and a healthy child.
For example, nine IVF/PGD cycles that
were initiated in four families having
mtDNA mutations resulted in just one
viable pregnancy (Sallevelt et al., 2013).2014 The Authors Open access under CC BY-NC-ND licFamilies with known mtDNA mutations
who are searching for reproductive op-
tions will likely be better served by
emerging methodologies that do not just
select, but actively eliminate, mutant
mtDNA in oocytes. In particular, spindle
transfer (Lee et al., 2012; Tachibana
et al., 2013) results in < 1%mutantmtDNA
carryover to the resulting embryo. This
reproductive technique will likely provide
a more reliable and effective medical
alternative to classical PGD for mtDNA
disease.
Until then, the current ambiguities of
PGD outcomes for families with mtDNA
mutations will require careful evaluation.
Further applications should be carried
out as a part of clinical trials under
appropriate regulatory oversight, to
ensure that parents are fully informed
about the experimental nature and high
risk of mtDNA mutation transmission to
offspring. Additionally, it is critical that all
children born after PGD are carefully fol-
lowed long-term to monitor any changes
in mtDNA mutation levels and associated
clinical symptoms.
Given the unpredictable nature of
changes in mtDNA heteroplasmy that
occur during development, further trans-
lational research investigations in rele-
vant animal models are warranted.
Research in rhesus macaques has pro-
vided a particularly valuable preclinical
experimental system in which to better
understand mechanisms of mtDNA in-
heritance and to develop novel treat-
ment options for the prevention of inter-
generational transmission of mtDNA
diseases (Lee et al., 2012; Tachibana
et al., 2013). We also highlight a need
for the development of additional animal
models of naturally arising pathogenic
mtDNA mutations that will be essential
for a better understanding of human
biology and disease.
We hope that the work of Steffann et al.
and our response will contribute to a
clearer understanding of the complexities
in predictingmtDNA disease transmission
and serve as a useful platform to stimulate
further discussions.SUPPLEMENTAL INFORMATION
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